• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Cullinan Therapeutics, Inc. - Common Stock (NQ:CGEM)

    17.84 -0.11 (-0.64%)
    Streaming Delayed Price Updated: 9:56 AM EDT, Aug 7, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 25,089
    Open 18.14
    Bid (Size) 17.67 (200)
    Ask (Size) 18.00 (200)
    Prev. Close 17.95
    Today's Range 17.52 - 18.43
    52wk Range 5.680 - 19.43
    Shares Outstanding 42,734,644
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Cullinan Therapeutics (NASDAQ:CGEM) Shares Jump on Inline Q2 Earnings and Pipeline Milestones ↗
    Via Chartmill
    News headline image
    Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +76.2%
    +76.2%
    1 Month
    -1.8%
    -1.8%
    3 Month
    +21.2%
    +21.2%
    6 Month
    +50.5%
    +50.5%
    1 Year
    +126.3%
    +126.3%

    More News

    Read More
    News headline image
    Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Why Marvell Technology Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket ↗
    Via Benzinga
    Topics Stocks
    Cullinan Therapeutics (NASDAQ:CGEM) Posts Narrower Q1 Loss, Eyes Key Clinical Data Catalysts ↗
    Via Chartmill
    News headline image
    Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
    From Taiho Oncology, Inc.
    Via Business Wire
    News headline image
    Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cullinan Therapeutics to Participate in Upcoming Investor Conferences
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cullinan Therapeutics to Participate in Fireside Chat at the Citi 2026 Virtual Oncology Leadership Summit
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    A Whole Watchlist of “Coiled Springs” (Found With One Simple ChartMill Screen) ↗
    Via Chartmill
    News headline image
    Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗
    Via The Motley Fool
    Topics Initial Public Offering Regulatory Compliance
    News headline image
    Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗
    Via The Motley Fool
    Topics Lawsuit Regulatory Compliance
    News headline image
    Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗
    Via The Motley Fool
    Topics Lawsuit Regulatory Compliance
    News headline image
    This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗
    Via The Motley Fool
    Topics Initial Public Offering Regulatory Compliance
    News headline image
    Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year ↗
    Via The Motley Fool
    Topics Regulatory Compliance

    Frequently Asked Questions

    Is Cullinan Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Cullinan Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Cullinan Therapeutics, Inc. - Common Stock trade on?
    Cullinan Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Cullinan Therapeutics, Inc. - Common Stock?
    The ticker symbol for Cullinan Therapeutics, Inc. - Common Stock is CGEM on the Nasdaq Stock Market
    What is the current price of Cullinan Therapeutics, Inc. - Common Stock?
    The current price of Cullinan Therapeutics, Inc. - Common Stock is 17.84
    When was Cullinan Therapeutics, Inc. - Common Stock last traded?
    The last trade of Cullinan Therapeutics, Inc. - Common Stock was at 08/07/26 09:56 AM ET
    What is the market capitalization of Cullinan Therapeutics, Inc. - Common Stock?
    The market capitalization of Cullinan Therapeutics, Inc. - Common Stock is 762.17M
    How many shares of Cullinan Therapeutics, Inc. - Common Stock are outstanding?
    Cullinan Therapeutics, Inc. - Common Stock has 762M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.